Denied on those, still holding 'em. Post each buy and sell and be assailed because of posting too frequently. Or post less often and be assailed for possibly reverse engineering history.
"Question why post like this when its not to be believed ? " Answer: why not.
Well the kids don't eat
And the dog can't sleep
There's no escape from the trading ...
07/27/15 9:32 AM EDT Buy 800 DVAX Executed @ $27.45
07/27/15 1:08 PM EDT Sell 800 DVAX Executed @ $28.15
It almost got bought out during the last (2nd) Heplisav PIII trial, and during the Heplisav PIII trial before that (1st). And before that almost bought out during the Tolamba PIII trial. 4th time is the charm.
Agree, nap time (hold). If you are not interested in trading, this one has great potential long term. Better potential than most biotechs IMO. But POTENTIAL. Any fledgling bio can crash and burn and DVAX with no approved compounds is fledgling. Mitigate your risk, don't "bet all." Should be just one of numerous investments and not a major percentage of your account.
Simple. Irrespective of Heplisav sales as long as they are good, that paves the door to more compounds, especially in the vaccine space.
If approved, the only gottcha would be more than expected SAEs in general population. A post-approval clinical hold would be disastrous. And cannot be 100% discounted.
No formula here, and occasionally have gotten stuck with shares a longer period, but excellent success. Off each failure to attain approval, it's inevitably been a back-and-forth but inexorably slow upward crawl. Perfrct to trade longwise.
Just staying long throughout would have cooked me. Hopefully this time is different and we get approval; nevertheless history dictates not going very big with FDA processes like VRBPAC impending.
The predictable cash raise via share issue is behind us now. Accompanying that of course could be increased short positions created by the institutions buying the new not-so-scarce shares. So SP will likely be volatile. But also most likely range-bound, hazarding a guess on the outer bounds, $25-$35, but likely mostly constrained within $27-$33.
One could leave a lot of moolah on the table by being passive and not trading this and instead endlessly predicting "to the moon" and "don't miss the train about to depart". I intend to bank moolah while listenting to the endless predictions, and smiling about them all the way to the bank.
The only things that take us outside the trading range as I see it:
VERY unlikely: unexpected good or bad clinical news Heplisav.
Unlikely: unexpected good or bad clinical news other programs
Unlikely: partnership changes to any programs inc Heplisav
VERY unlikely: bid made for company
The better trade by far appears to be long-wise, short-wise is dangerous as more of the unlikely news is to the positive side.
Where from here?
looking down on empty streets, all Gray can see
are the dreams all made solid
are the dreams all made real
all of the buildings, all those vaccines
were once just a dream
in somebody's head
Speaking of 30's. just added back 500 trading shares @28.35 *